1. Home
  2. FTH vs BWAY Comparison

FTH vs BWAY Comparison

Compare FTH & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Faeth Therapeutics Inc. Common Stock

FTH

Faeth Therapeutics Inc. Common Stock

N/A

Current Price

$21.84

Market Cap

507.8M

Sector

Health Care

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$11.14

Market Cap

446.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTH
BWAY
Founded
1999
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
507.8M
446.4M
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
FTH
BWAY
Price
$21.84
$11.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
3
Target Price
★ $55.31
$19.27
AVG Volume (30 Days)
★ 351.3K
85.4K
Earning Date
11-03-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$32.42
Revenue Next Year
N/A
$23.40
P/E Ratio
★ N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$16.57
$10.94
52 Week High
$42.14
$26.63

Technical Indicators

Market Signals
Indicator
FTH
BWAY
Relative Strength Index (RSI) 46.98 41.15
Support Level $16.57 N/A
Resistance Level $21.97 $12.12
Average True Range (ATR) 2.02 0.44
MACD 0.65 0.01
Stochastic Oscillator 87.41 32.98

Price Performance

Historical Comparison
FTH
BWAY

About FTH Faeth Therapeutics Inc. Common Stock

Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: